SLC5A2 and type 2 diabetes mellitus: Given that DED affects about one-fifth of patients with T2D and reduces the patients’ quality of life,4,5 our findings with the small absolute risk difference (2.5 per 1000 person-years) between SGLT2 inhibitors and GLP-1 RAs may provide an important reference for clinical decisions about prescribing different antidiabetic medications to delay or prevent DED in patients with T2D.